Assessment of Single cell RNA sequencing of Relapsing-remitting Multiple-sclerosis CSF to identify the changes in cell type proportions following reconstitution after Natalizumab treatment
Latest Information Update: 20 Dec 2022
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 28 Oct 2022 Results presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 25 Mar 2021 New trial record
- 27 Feb 2021 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021